Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YIFAN TU

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1447405899
CMS profile
1294175
Location
ST. LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$3,230.50

141 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,230.50 141

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YIFAN TU

NPI 1447405899 · CMS profile ID 1294175

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ST. LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447405899?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YIFAN TU, NPI 1447405899, CMS profile ID 1294175. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447405899?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). YIFAN TU, NPI 1447405899, CMS profile ID 1294175. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447405899?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
YIFAN TU, NPI 1447405899, CMS profile ID 1294175, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1447405899?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

141 matching records · $3,230.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 141 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–141 of 141.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Karyopharm Therapeutics Inc. $24.8505/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946532233 CMS
SERVIER PHARMACEUTICALS LLC $14.1005/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964207819 CMS
Merck Sharp & Dohme LLC $14.3405/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944316189 CMS
Janssen Biotech, Inc. $29.7805/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886098261 CMS
Novartis Pharmaceuticals Corporation $16.7905/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894425245 CMS
E.R. Squibb & Sons, L.L.C. $18.1904/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932865811 CMS
Rigel Pharmaceuticals, Inc. $13.1004/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962271395 CMS
MorphoSys, US Inc. $14.1204/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962538241 CMS
Novartis Pharmaceuticals Corporation $20.4304/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894425243 CMS
GlaxoSmithKline, LLC. $15.2904/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945056805 CMS
Lilly USA, LLC $19.2904/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918445509 CMS
ABBVIE INC. $16.5204/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892557461 CMS
Regeneron Healthcare Solutions, Inc. $122.7804/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927451737 CMS
AstraZeneca Pharmaceuticals LP $21.9604/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915056353 CMS
Novartis Pharmaceuticals Corporation $21.0204/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894425241 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $11.7204/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887692275 CMS
Janssen Biotech, Inc. $21.2904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886098291 CMS
Amgen Inc. $27.8404/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939895889 CMS
Seagen Inc. $19.2303/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904119555 CMS
EISAI INC. $18.9803/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908098985 CMS
Global Blood Therapeutics, Inc. $17.3703/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942709825 CMS
E.R. Squibb & Sons, L.L.C. $15.9103/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932865801 CMS
AVEO Pharmaceuticals, Inc. $15.0403/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950108013 CMS
ADC Therapeutics America, Inc. $17.7903/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060940957 CMS
E.R. Squibb & Sons, L.L.C. $18.6602/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932865795 CMS
Amgen Inc. $18.2902/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939328903 CMS
GENZYME CORPORATION $19.2702/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938994025 CMS
Incyte Corporation $16.3302/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943008595 CMS
Kite Pharma, Inc. $15.0302/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920061715 CMS
Rigel Pharmaceuticals, Inc. $15.0702/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962267927 CMS
Amgen Inc. $13.2302/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939328907 CMS
Seagen Inc. $8.9602/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904119551 CMS
Celgene Corporation $19.4101/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932865793 CMS
Genentech USA, Inc. $18.4501/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950802185 CMS
Genentech USA, Inc. $17.4901/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950802187 CMS
Blueprint Medicines Corporation $45.5901/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958937539 CMS
Adaptive Biotechnologies Corporation $16.1801/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951428285 CMS
Daiichi Sankyo Inc. $12.3401/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930795583 CMS
Janssen Biotech, Inc. $16.2601/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886098267 CMS
Epizyme, Inc., $16.6901/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917612447 CMS
Amgen Inc. $25.2501/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939895887 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,630.85 17
PY2020 $236.07 7
PY2021 $3,714.39 48
PY2022 $3,230.50 141
PY2023 $10,640.98 164
PY2024 $21,598.66 188
PY2025 $16,495.21 170

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $303,208.08 67
PY2024 Recipient $1,740.96 8
PY2024 Principal investigator $57,038.00 5
PY2019 Principal investigator $2,345.75 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,738.35 12/04/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184269407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,797.15 11/07/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184257823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,944.25 10/29/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184253752
Principal investigator 1 GlaxoSmithKline, LLC. $3,200.00 09/26/2025 Non-covered Recipient Entity
MERCY RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192124006
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 09/26/2025 Non-covered Recipient Entity
MERCY RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192124011
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/26/2025 Non-covered Recipient Entity
MERCY RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192126607
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 09/17/2025 Non-covered Recipient Entity
Mercy Medical Research Institute
DS7300-188 No dispute reported 06/30/2026 1223372928
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 09/17/2025 Non-covered Recipient Entity
Mercy Medical Research Institute
DS7300-188 No dispute reported 06/30/2026 1223372930
Principal investigator 1 Daiichi Sankyo Inc. $13,900.00 09/17/2025 Non-covered Recipient Entity
Mercy Medical Research Institute
DS7300-188 No dispute reported 06/30/2026 1223372932
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,842.05 09/12/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184236676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,833.80 08/26/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184230455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $112.50 07/31/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184222934
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,036.20 07/31/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184222936
Principal investigator 1 GlaxoSmithKline, LLC. $2,200.00 07/14/2025 Non-covered Recipient Entity
MERCY RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192126594
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 07/14/2025 Non-covered Recipient Entity
MERCY RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192126601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,009.95 07/04/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184212951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,009.95 06/12/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184206469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,000.00 06/12/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184206471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,525.00 06/12/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184206473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,589.00 06/12/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184206475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/12/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184206477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,000.00 05/28/2025 Non-covered Recipient Entity
MERCY RESEARCH
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184199179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,184.00 05/28/2025 Non-covered Recipient Entity
MERCY RESEARCH
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184199181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,548.00 05/28/2025 Non-covered Recipient Entity
MERCY RESEARCH
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184199183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,517.00 05/28/2025 Non-covered Recipient Entity
MERCY RESEARCH
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184199185
Principal investigator 1 PFIZER INC. $1,000.00 05/23/2025 Non-covered Recipient Entity
Mercy Research
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228855406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,009.95 05/22/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184197687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,752.20 05/15/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184194825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,661.60 05/15/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184194827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,470.10 05/08/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184193789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/02/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,534.00 05/02/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,000.00 05/02/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184191965
Principal investigator 1 AstraZeneca Pharmaceuticals LP $102,597.23 04/30/2025 Non-covered Recipient Entity
MERCY
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185545333
Principal investigator 1 GlaxoSmithKline, LLC. $900.00 04/29/2025 Non-covered Recipient Entity
MERCY RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192124016
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,018.60 04/15/2025 Non-covered Recipient Entity
MERCY MEDICAL RESEARCH INSTITUTE
A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC No dispute reported 06/30/2026 1184183204
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 03/31/2025 Non-covered Recipient Entity
MERCY RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192124023
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,958.00 02/21/2025 Non-covered Recipient Entity
MERCY RESEARCH
a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 No dispute reported 06/30/2026 1185545331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 02/20/2025 Non-covered Recipient Entity
MERCY RESEARCH
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184154898
Principal investigator 1 Daiichi Sankyo Inc. $154.65 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372872
Principal investigator 1 Daiichi Sankyo Inc. $44.70 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372874
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372876
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372878
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372880
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372882
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372884
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372886
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372888
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372890
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372892
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372894
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372896
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372898
Principal investigator 1 Daiichi Sankyo Inc. $91.25 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372900
Principal investigator 1 Daiichi Sankyo Inc. $30.80 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372902
Principal investigator 1 Daiichi Sankyo Inc. $29.25 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372904
Principal investigator 1 Daiichi Sankyo Inc. $4.25 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372906
Principal investigator 1 Daiichi Sankyo Inc. $20.85 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372908
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372910
Principal investigator 1 Daiichi Sankyo Inc. $50.15 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372912
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372914
Principal investigator 1 Daiichi Sankyo Inc. $86.30 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372916
Principal investigator 1 Daiichi Sankyo Inc. $75.00 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372918
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372920
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372922
Principal investigator 1 Daiichi Sankyo Inc. $15.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372924
Principal investigator 1 Daiichi Sankyo Inc. $46.50 01/10/2025 Non-covered Recipient Entity
Mercy Clinic Oncology And Hematology
DS7300-188 No dispute reported 06/30/2026 1223372926